Interferon is currently considered to be the only accepted effective treatment for chronic viral hepatitis. A history of the treatment of chronic hepatitis B and C before the use of interferon is presented here. Hepatitis B virus does not seem to be directly cytopathic and the disease is known to be modulated largely by the host's immune response. Experience with immunosuppressant and immunosti...

introduction: chronic hepatitis b and c will result in limitations of physical and mental functions which in turn reduces the quality of life of the patients. this study examines the quality of life in patients with chronic hepatitis b and c in rasht razi hospital between the period of 2003-2004. materials and methods: in this cross- sectional study, 74 patients with chronic hepatititis living ...

BACKGROUND/AIMS The aim of the study was to assess bone metabolism and impact of disease on bone mineral density in patients with non-cirrhotic chronic hepatitis B or C. METHODS 105 patients with chronic hepatitis B or C receiving antiviral agents and 60 healthy controls were included. Subgroups (n=15) were defined on the basis of age (males) or menopausal status (females). Bone mineral densi...

conclusions the use of sof + pr regimen or ldv/sof can significantly reduce the incidence of complications associated with the disease. for example, short and long-term outcomes are better than the current drug regimens for hcv genotype 1 patients in all stages of the disease. objectives this study is aimed to assess the cost-effectiveness of the three drug regimens of pegylated interferon and ...

conclusions according to the results, total direct medical costs for hcv patients in iran exceeded 12 billion ppp$ in (inf-rbv) treatment and 55 billion ppp$ in (peg-rbv). results average direct medical costs for the courses treated with conventional interferon plus ribavirin (inf-rbv) were 4,403 ppp$, and 20,010 ppp$ for peg-interferon plus ribavirin (peg-rbv) courses. there was an increase of...

background pegylated interferon alfa plus ribavirin protocol is currently considered the most efficient hepatitis c treatment. however, no evidence of costs comparison among common viral genotypes has been published. objectives we aimed to assess core drivers of hepatitis c medical care costs and compare cost effectiveness of this treatment among patients infected by hepatitis c virus with geno...

background rapid virological response (rvr) strongly predicts sustained virological response (svr) in patients with chronic hepatitis c (chc), and abbreviates antiviral therapy in some patients. objectives to identify factors predicting virological relapse (vr) in chc patients who attained rvr. patients and methods medical records of 133 chc patients with an rvr after completing 24 weeks of ant...

hepatitis b virus (hbv) is a crucial public health problem with approximately 350 million affected people and a death rate of 0.5 to 1.2 million per year worldwide. it proceeds to end-stage liver diseases including cirrhosis with hepatic decompensation and hepatocellular carcinoma (hcc). pakistan lies in the endemic region with 3% hbv carrier rate in the country. the differences in disease outc...

Introduction: Hepatitis B and C are major health problems in many countries, especially developing areas. The frequency of hepatitis B is less than 0.8%, and chronic hepatitis C is less than 0.5% in the general population of Yazd in the center of Iran. Large vehicle drivers have some risk factors for acquiring hepatitis B and C infection. This is important because viral hepatitis complications,...

This preliminary study was designed to evaluate the effects of Heberon Alfa for the treatment of chronic hepatitis B infected subjects in Iran. A single center, open label, single treatment prospective study of Interferon Alfa (Heberon Alfa), 5 million units every other day for a period of 4 months, was performed between 1996 to 1998. A total number of 30 patients with histologically docume...